Rising Demand for Animal Protein and Intensive Livestock Production
The high demand for meat, dairy, and other animal products by the global population is driving the animal vaccines market. Increasing demand for meat requires intensive animal farming methodologies to achieve maximum production efficiency and satisfy consumption requirements. For such high-density animal populations, the risk of disease outbursts is greatly increased, prompting vaccination to act as a key preventive measure. For instance, based on the US Foreign Agricultural Service's Livestock and Poultry: World Markets and Trade report, by January 2024, indicated 87.8 million head of cattle and 74.97 million swine in the United States. The preservation of the health of such huge herds with mass vaccination has a direct bearing on food security and economic stability within the agricultural economy. Governments and industry organizations are increasingly adopting mandatory vaccination programs to protect animal health, control the spread of contagious diseases, and assure public safety of the food chain. The initiative reflects the integral role played by animal vaccines in animal husbandry.
Increased Rate of Zoonotic Disease & Increasing Public Health Awareness
The rising incidence of diseases that can be transmitted between animals & humans is driving the market of animal vaccines. Avian flu, rabies, and swine flu are among the key zoonotic diseases whose severity would result in extreme public health crises and cause catastrophic economic damage. Governments, veterinarians, and pet owners have, therefore, become increasingly aware of the need for preventive healthcare, through which the spread of disease is halted through the process of vaccination. For instance, the World Health Organization (WHO) constantly emphasizes the interconnection of animal & human health, encouraging a "One Health" policy. This focus stimulates research and development into new vaccines that can be used for animal population protection and, in turn, human health. The need to combat such diseases and avert future pandemics is propelling investments in animal vaccine research and development as well as general vaccination efforts.
Advancements in Vaccine Technology and Research & Development
Remarkable innovations in vaccine technology, such as the advancement of DNA, recombinant, and subunit vaccines, offer huge opportunities for market expansion. These newer generations of vaccines feature increased efficacy, safety, and specially tailored protection against particular pathogens with fewer side effects than conventional vaccines. Continued intense research and development initiatives are resulting in new antigens and better vaccine delivery systems. This innovation pipeline, in addition to rising investments from pharmaceutical industries and government agencies, is setting the stage for the launch of very effective vaccines for both emerging and endemic animal diseases. For instance, the ongoing research into mRNA technology, witnessed in the recent human health emergency, presents unprecedented potential for the speedy development and deployment of animal vaccines in the face of emerging disease threats, expanding the market's reach.
Increased Pet Ownership and Companion Animal Healthcare Expenditure
Increased pet adoption and the humanization of companion animals worldwide are generating considerable opportunities in the animal vaccines market. Pet owners are willing to spend money on their pets' health and comfort, considering them as part of the family. This demographic trend is reflected in higher demand for preventive care, in the form of regular vaccinations against major prevalent diseases such as rabies, distemper, and parvovirus. Companion animal healthcare spending keeps increasing year after year, based on several pet industry reports. This emerging market segment stimulates manufacturers to design a broader variety of vaccines designed specifically for companion animals, usually with emphasis on administration convenience and wider spectrum protection. The psychological connection between owners and companions guarantees a stable and expanding market for companion animal vaccines.
The following Key Market Indicators present a comprehensive overview of the social and economic landscape of the selected region, offering critical insights into market-specific trends and developments. These indicators, combined with data from government statistics, industry associations, and corporate sources, form the analytical foundation of NextGen Intelligence Stats' market models.
| Aspects | Details |
Base Year
|
2024 |
Historic Data
|
2021-2024 |
Forecast Period
|
2025-2035 |
Regions & Countries Covered
|
North America (United States, Canada), Europe (Germany, France, Italy, United Kingdom, Spain, Rest of Europe), Asia Pacific (China, Japan, South Korea, India, Rest of Asia Pacific), Latin America (Brazil, Argentina, Rest of Latin America), Middle East& |
Companies Profiles
|
|
Segmentation Level Customization
|
|
Company Level Customization
|
|
Country level Data Customization
|
Segmental volume analysis Pricing Analysis of Product Company Market Share |
November 2024: Bioveta a.s. International debuted its Biocan Novel Vaccines line in India. The expansion was a five-city mission to Bengaluru, Chennai, Kolkata, Delhi, and Mumbai to launch the range of canine vaccines, further cementing the company's international mission to fight infectious diseases, including rabies.
August 2024: Indian Immunologicals Limited (IIL), along with the Indian Council of Agricultural Research-Central Institute of Brackishwater Aquaculture (ICAR-CIBA), achieved great strides in the development of their fish vaccine, "Nodavac-R." This cooperation will focus on solving essential health problems of the aquaculture industry.
July 2024: Biogénesis Bagó opened a new vaccine manufacturing facility in Campo Largo, Brazil, marking an investment of $30 million. The plant will be the largest veterinary vaccine manufacturer in Latin America, increasing the company's capacity for production & regional presence.
July 2024: Dechra Pharmaceuticals Limited confirmed acquisition of Invetx, a biopharmaceutical company dedicated to the discovery & development of protein-based therapies for chronic diseases in companion animals, with a particular emphasis on monoclonal antibodies (mAbs). The acquisition is consistent with Dechra's long-term aspiration to be an innovation leader and acquire an exciting pipeline of innovative products in dogs and cats.
November 2023: Bimeda officially launched its new Shijiazhuang state-of-the-art sterile injectable manufacturing plant in China. This €25m+ expansion greatly increases Bimeda's worldwide manufacturing capacity and enhances its position in the Asian market.
The global animal vaccines market is dominated by a combination of large multinational companies having international presence, as well as regional specialists. Major market players fiercely compete based on product innovation, product portfolio range, geographical presence, and strategic partnerships. Mergers and acquisitions along with partnerships are common tactics to increase market share, diversify product lines, and access emerging markets. Firms also expand their distribution networks, such as direct to veterinary practice and through e-commerce platforms, to make the products more widely available. The competitive dynamics in the marketplace are also influenced by ongoing requirements for speedy reaction to changing disease challenges and regulatory requirements, leading to continuous investment in research and development to have a differential advantage and meet unmet needs in animal health.
• Biogénesis Bagó
• Bioveta
• Bimeda Biologicals
• Boehringer Ingelheim
• Brilliant Bio Pharma
• Calier
• Ceva
• Dechra Pharmaceuticals
• Durvet
• Elanco
• Henry Schein Animal Health
• Hester Biosciences Limited
• HIPRA
• Indian Immunologicals Ltd.
• Jinyu Biotechnology Co., Ltd.
• Kemin Industries, Inc.
• LETI Pharma
• Merck & Co., Inc.
• Neogen Corporation
• Ourofino
• Phibro Animal Health Corporation
• Vaxxinova
• Vetoquinol
• Virbac
• Zoetis
• Others
Global Animal Vaccine Market continues on a promising upward trajectory, with revenue expected to increase from around US$ 13.36 billion in 2024 to nearly US$ 34.48 billion by 2035, registering a strong CAGR of 8.5% over the forecast period.
Animal Vaccines market registering a strong CAGR of 8.5% over the forecast period.
Rising Demand for Animal Protein and Intensive Livestock Production, Increased Rate of Zoonotic Disease & Increasing Public Health Awareness, Advancements in Vaccine Technology and Research & Development, Increased Pet Ownership and Companion Animal Healthcare Expenditure
North America grabbed 27.6% share in the market, driven by its highly developed veterinary health infrastructure, pet population rates, and sophisticated livestock farming activities.
North America Animal Vaccines Market share, 2024
Source: NextGen Intelligence Stats and Consulting LLP
Asia-Pacific is the fastest-growing region in the animal vaccines market, which is expected to have a CAGR of 10.7% in the forecast period. This growth is largely spurred by the region's fast-growing livestock and aquaculture industries, which are fuelled by rising demand for animal protein from its huge and expanding population. Furthermore, growing pet ownership in nations such as China and India, along with growing consciousness of animal health and welfare. Friendly government policies promoting animal health programs and growing investment in veterinary infrastructure also contributes to segment growth.
North America grabbed 27.6% share in the market, driven by its highly developed veterinary health infrastructure, pet population rates, and sophisticated livestock farming activities. Tough government regulations around control of animal diseases and food safety add fuel to vaccine demand. The region enjoys high levels of investment in animal health R&D, having been the first to implement cutting-edge vaccine technologies.
1.1. Introduction
1.2. Report Description & Objective
1.3. Assumption And Limitation
2.1. Data Collection
2.2. Primary Research & Secondary Research
2.3. Bottom-Up Approach & Top-Down Approach
2.4. Market Analysis & Size Estimation
2.5. Quality Check & Final Review
3.1. Report Scope
3.2. Executive Summary
4.1. Top Trends To Watch
4.2. Top Strategies Followed By Key Players
4.3. Top Investment Pockets
5.1. Market Definition
5.2. Market Drivers
5.3. Market Restraints & Challenges
5.4. Market Opportunities
6.1. Porter’s Five Forces’ Analysis
6.2. Value Chain Analysis / Supply Chain Analysis
6.3. PESTLE Analysis
6.4. Regulatory Landscape
6.5. Pricing Analysis
7.1. Global Animal Vaccines Market, By Animal Type
7.2. Global Animal Vaccines Market Attractiveness, By Animal Type
7.2.1. Livestock animals
7.2.1.1. Poultry
7.2.1.2. Cattle
7.2.1.3. Swine
7.2.1.4. Aquaculture
7.2.1.5. Sheep and goats
7.2.2. Companion animals
7.2.2.1. Canine
7.2.2.2. Feline
7.2.2.3. Equine
7.2.2.4. Avian
8.1. Global Animal Vaccines Market, By Vaccine Type
8.2. Global Animal Vaccines Market Attractiveness, By Vaccine Type
8.2.1. Attenuated live vaccine
8.2.2. Conjugate vaccine
8.2.3. Inactivated vaccine
8.2.4. DNA vaccine
8.2.5. Recombinant vaccine
8.2.6. Others
9.1. Global Animal Vaccines Market, By Application
9.2. Global Animal Vaccines Market Attractiveness, By Application
9.2.1. Injection vaccines
9.2.2. Oral vaccines
9.2.3. Immersion/spray vaccines
10.1. Global Animal Vaccines Market, By Route of Administration
10.2. Global Animal Vaccines Market Attractiveness, By Route of Administration
10.2.1. Veterinary hospital pharmacies
10.2.2. Retail pharmacies
10.2.3. E-commerce
11.1. Global Animal Vaccines Market, By Geography
11.2. Global Animal Vaccines Market Attractiveness, By Geography
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Middle East & Africa
11.2.5. Latin America
12.1. North America Market Overview, By Countries
12.2. North America Market Overview, By Animal Type
12.3. North America Market Overview, By Vaccine Type
12.4. North America Market Overview, By Application
12.5. North America Market Overview, By Route of Administration
12.5.1. United States
12.5.2. Canada
13.1. Europe Market Overview, By Countries
13.2. Europe Market Overview, By Animal Type
13.3. Europe Market Overview, By Vaccine Type
13.4. Europe Market Overview, By Application
13.5. Europe Market Overview, By Route of Administration
13.5.1. Germany
13.5.2. France
13.5.3. UK
13.5.4. Italy
13.5.5. Spain
13.5.6. Rest of Europe
14.1. Asia Pacific Market Overview, By Countries
14.2. Asia Pacific Market Overview, By Animal Type
14.3. Asia Pacific Market Overview, By Vaccine Type
14.4. Asia Pacific Market Overview, By Application
14.5. Asia Pacific Market Overview, By Route of Administration
14.5.1. India
14.5.2. China
14.5.3. Japan
14.5.4. South Korea
14.5.5. Rest of Asia Pacific
15.1. Middle East & Africa Market Overview, By Countries
15.2. Middle East & Africa Market Overview, By Animal Type
15.3. Middle East & Africa Market Overview, By Vaccine Type
15.4. Middle East & Africa Market Overview, By Application
15.5. Middle East & Africa Market Overview, By Route of Administration
15.5.1. GCC
15.5.2. South Africa
15.5.3. Rest of Middle East & Africa
16.1. Latin America Market Overview, By Countries
16.2. Latin America Market Overview, By Animal Type
16.3. Latin America Market Overview, By Vaccine Type
16.4. Latin America Market Overview, By Application
16.5. Latin America Market Overview, By Route of Administration
16.5.1. Brazil
16.5.2. Argentina
16.5.3. Rest of Latin America
17.1. Key Developments
17.1.1. Partnerships, Collaborations, Agreements
17.1.2. Mergers & Acquisitions
17.1.3. New Product Developments
17.1.4. Other Developments
17.2. Company Share Analysis
17.3. Company Profiles
17.3.1. Biogénesis Bagó
17.3.1.1. Company Overview
17.3.1.2. Product Overview
17.3.1.3. Financial Insights
17.3.1.4. Recent Developments
17.3.1.5. SWOT Analysis
17.3.2. Bioveta
17.3.3. Bimeda Biologicals
17.3.4. Boehringer Ingelheim
17.3.5. Brilliant Bio Pharma
17.3.6. Calier
17.3.7. Ceva
17.3.8. Dechra Pharmaceuticals
17.3.9. Durvet
17.3.10. Elanco
17.3.11. Henry Schein Animal Health
17.3.12. HESTER BIOSCIENCES LIMITED
17.3.13. HIPRA
17.3.14. Indian Immunologicals Ltd.
17.3.15. Jinyu Biotechnology Co., Ltd.
17.3.16. Kemin Industries, Inc.
17.3.17. LETI Pharma
17.3.18. Merck & Co., Inc.
17.3.19. Neogen Corporation
17.3.20. Ourofino
17.3.21. Phibro Animal Health Corporation
17.3.22. Vaxxinova
17.3.23. Vetoquinol
17.3.24. Virbac
17.3.25. Zoetis
Data Collection
Primary Research & Secondary Research
Bottom-Up Approach & Top-Down Approach
Market Analysis & Size Estimation
Quality Check & Final Review
By Animal Type
• Livestock animals
o Poultry
o Cattle
o Swine
o Aquaculture
o Sheep and goats
• Companion animals
o Canine
o Feline
o Equine
o Avian
By Vaccine Type
• Attenuated live vaccine
• Conjugate vaccine
• Inactivated vaccine
• DNA vaccine
• Recombinant vaccine
• Other vaccine types
By Application
• Bacterial infections
• Viral infections
• Parasitic infections
• Fungal infections
• Other applications
By Route of Administration
• Injection vaccines
• Oral vaccines
• Immersion/spray vaccines
By Distribution Channel
• Veterinary hospital pharmacies
• Retail pharmacies
• E-commerce
© NextGen Intelligence Stats and Consulting LLP All rights reserved.
